



# **iJRASET**

International Journal For Research in  
Applied Science and Engineering Technology



---

# **INTERNATIONAL JOURNAL FOR RESEARCH**

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

---

**Volume: 13    Issue: IV    Month of publication: April 2025**

**DOI: <https://doi.org/10.22214/ijraset.2025.69245>**

**[www.ijraset.com](http://www.ijraset.com)**

**Call:  08813907089**

**E-mail ID: [ijraset@gmail.com](mailto:ijraset@gmail.com)**

# Review on Adverse Drug Reaction

Mr. Vijay Dabade<sup>1</sup>, Ms. Pooja Gaikwad<sup>2</sup>, Mr. Prathamesh Gaikwad<sup>3</sup>, Ms. Shweta Navale<sup>4</sup>, Mr. Akash Badhe<sup>5</sup>, Mr. Nitin Gawai<sup>6</sup>

B Pharmacy Department, Mahadev Kanchan College of Pharmaceutical Education & Research, Uruli Kanchan, Pune, Maharashtra, India

**Abstract:** ADVERSE drug reactions (ADRs) continue to pose a challenge in contemporary healthcare, especially due to the growing complexity of treatments, an older population, and an increase in multimorbidity. This article outlines several key details regarding ADRs and examines elements associated with their prevention, diagnosis, reporting, and management to assess the occurrence of fatal adverse drug reactions (FADRs) within a population. Adverse drug reactions (ADRs) pose a significant public health issue, serving as a leading cause of illness and death. Nonetheless, multiple countries lack recent studies. Since 2014, a forward-looking active pharmacovigilance initiative, designed to enhance ADRs monitoring in hospital units (FORWARD), has been conducted in Sicily. Adverse Drug Reactions (ADRs) pose a major issue in clinical practice, impacting patient safety and the results of treatment. This review examines different kinds of ADRs, highlighting the significance of a precise medication history in detecting possible reactions. We examine the materials and techniques employed for ADR detection and provide examples to demonstrate the clinical significance of these reactions. The document emphasizes the essential elements of ADR reporting, such as evaluating severity, preventability, and causation, offering an in-depth insight into how these aspects affect clinical management. Moreover, we investigate methods to improve medication safety, which includes enhancing ADR. This research, as part of the FORWARD project, aimed to outline ADRs that occurred during the hospitalization in Internal Medicine departments. ADRs connected to hospital admissions, their characteristics, and the possibility of prevention were also assessed. In this review, we cover the categories of ADRs, medication history, materials and methods, examples of ADRs, the reporting process for ADRs, their severity, preventability, and causation, as well as strategies to improve medication safety.

**Keywords:** ADRs, drug reaction, DoTS, Medication, patient, illness, withdrawal, severity, safety.

## I. INTRODUCTION

An Adverse Drug Response (ADR) can be defined as ‘an appreciably dangerous or unwelcome response performing from an intervention related to the use of a medicinal product; adverse goods generally prognosticate hazard from unborn administration and leave forestallment, or specific treatment, or revision of the lozenge authority, or pullout of the product’. An adverse drug reaction (ADR) is characterized as ‘an significantly adverse or disagreeable response stemming from an intervention concerning the use of a pharmaceutical product; negative effects typically anticipate risk from upcoming administration and guarantee prevention, or particular treatment, or modification of the dosing schedule, or cessation of the product. Because Since 2012, the definition has encompassed reactions taking place as a outcome of mistakes, misapplication or mistreatment, and to anticipated responses to medications that are not authorized or are utilized beyond their approved indications besides the permitted use of a pharmaceutical product in typical amounts. Although this modification may change the monitoring and oversight conducted by producers and medication authorities, in medical practice it ought not to influence our method for handling ADRs. (1)

Since 2012, the description has included responses being as a result of error, abuse or abuse, and to suspected responses to drugs that are unlicensed or being used off- marker in addition to the authorized use of a medicinal product in normal boluses. Adverse drug reactions (ADR) are a key issue to be evaluated in contemporary society. According to the World Health Organization (WHO), an ADR is defined as any harmful and unintended reaction to a medication. that happens at doses utilized in humans for the prevention, identification, or treatment of illness; or for the alteration of Physiologic function deliberately omits therapeutic failures, overdosing, substance misuse, non-adherence, and medication issues. mistakes. Additionally, it has been considered a significant adverse response stemming from an intervention associated with the utilization of healthcare items. An unwanted outcome, which arises as an exaggeration of the intended therapeutic effect, constitutes a component of ADR, on the other hand, side effects are typically associated with the therapeutic effects of a drug that can be advantageous as well as harmful. Therefore, it can be proposed that an ADR is a detrimental response or an undesired reaction that occurs after the application of a medicinal product or a mixture of drugs under typical usage conditions.

Nonetheless, different kinds of ADRs have been documented, encompassing type A, type B, and type C adverse reactions. Type A ADRs are frequently pertaining to dosage that amplify the usual therapeutic impact of medication, along with typical causes of overdose and modification of the dosage, while type B have been regarded as the idiosyncratic reactions that tend to be rare and unpredictable. & not linked to the drug's pharmacological effects; and type C ADRs have been proposed to be associated with long-term medication treatments that produce both significant and ordinary impacts on public health occur. This review currently This article intends to address the different kinds of adverse drug reactions. (2)

While this change potentially alters the reporting and surveillance carried out by manufactures and drugs controllers, in clinical practice it shouldn't affect our approach to managing ADRs. (1)

Adverse medicine responses (ADR) represent one of the high motifs to be assessed in the ultramodern times. According to world health association (WHO), an ADR can be defined as any response of a medicine which is noxious and unintended, that occurs at boluses used in humans for the prophylaxis, opinion or remedy of complaint; or for the revision of physiologic function deliberately excludes remedial failures, overdoes, medicine abuse, non-compliance, and drug crimes. also, it has been regarded as a perceptible dangerous response which results from an intervention related to the use of a medical products. An adverse effect, which occurs as overdo of the asked remedial effect, forms a part of ADR, whereas, side goods are generally related to the remedial conditioning of a medicine which may be salutary as well as dangerous. therefore, it may be suggested that an ADR is a dangerous response or unwanted response that's followed by the administration of a medicinal product or a combination of medicines under normal conditions of use. still, colorful type of ADRs have been reported which include type A, type B and type C adverse responses. (2)

The pharmacological bracket of adverse medicine responses whose reason has been established presently rests on the perceived cure dependence and pungency of the adverse response. (3)

The mounting evidence regarding the heightened occurrence and intensity of ADRs, which negatively affects a patient's health status, further indicates that ADRs impose a substantial burden on healthcare institutions, extending hospital stays and sometimes necessitating extra investigations and medication treatments for the symptoms and ailments inflicted on the patient. (4)

Adverse Drug Responses (ADRs) constitute a major problem for the existent as well as for the community. In former studies, the frequency of sanitarium admissions due to ADRs ranged from 2.4 to 12.0. (5)

## II. CLASSIFICATION

Traditionally, ADRs have been classified into 4 types:

- 1) *Type A responses – (occasionally appertained to as stoked responses)* which are 'cure-dependent' and predictable on the base of the pharmacology of the medicine.(1) The pharmacodynamic factors behind type A reactions consist of liver disease, and changes in fluid and electrolyte balance, changed sensitivity and prolonged impacts. The liver disease has been demonstrated to influence the pharmacodynamic reaction of a medication and result in an adverse drug reaction due to the generation of clotting factor. Additionally, the medication must be prevented from affecting clotting or causing disruption. hemorrhaging through the formation of ulcers. Hypokalemia and hypercalcemia, resulting from cardiac glycoside, have been observed. to become enhanced, leading to pharmacodynamic changes that ultimately result in type A adverse reactions. Furthermore, type A Negative effects have been recorded to be associated with the drug's pharmacological properties. Nevertheless, effects of type A can generally be replicated and examined in experiments. (2)
- 2) *Type B responses – (crazy responses)* which are idiosyncratic and not predictable on the base of the pharmacology. (1) Type B adverse effects have been observed in a limited number of patients and are frequently sensitive or unique reactions. Furthermore, type B adverse reactions are thought to be unexpected and unpredictable; exhibiting less or no connection with the amount administered. Nonetheless, the connection with time and minimal background frequency is typically the primary grounds for doubting the drug's impact on type B effects. Additionally, type B ADRs can be categorized as non-immunological ADRs, that are additionally classified into predictable and unpredictable responses resulting from overdose, combined effects, gradual toxicity, interactions of drugs, alteration of metabolism, teratogenic effects, worsening of diseases, drug-induced chromosomal changes disruption and intolerance; as well as immunological ADRs that are unpredictable and arise from immunoglobulin (Ig) E-dependent medication reactions, immune complex-mediated drug reactions, cytotoxic drug-triggered responses, and cell facilitated responses.
- 3) *Type C adverse responses:* It have been attributed to both serious and common goods having notable issues on public health from habitual complaint venom. also, type C responses have been regarded as the responses with habitual goods related to long-term medicine use, similar as analgesic nephropathy or extrapyramidal goods. These responses have been set up to relate to the accretive poisonous goods of a medicine used over time, in which the adverse goods increase gradationally. In addition, the



type C responses have been suggested as the long-term medicine goods including adaptive changes and pullout goods. Type C adverse responses have been known to be habitual in nature associated with long-term medicine remedy, which can be substantiated by the fact that the induction of iatrogenic hyperadrenocorticism occurs with habitual use of prednisolone or other corticosteroids. In addition, studies have reported the adaption on termination of the medicine, generally appertained to as abstinence pattern.(2)

- 4) Type D responses It also nominated as delayed ADRs, are the responses that have been set up to be apparent after eventually of the treatment. The development of secondary cancers in cases treated with alkylating agents like cyclophosphamide is the stylish illustration of type D adverse responses. In addition, type E ADRs have been known to do when medicine treatment has been terminated suddenly, the exemplifications of which include pullout seizures on terminating anticonvulsant remedy and adrenocortical insufficiency posterior to glucocorticoids termination.(2)

New approach to classifying adverse drug responses (DOTs Classification)

a) *Dose Relatedness*

Traditionally, immunological and certain other adverse drug responses have been considered not to be cure related. still, goods of drugs involve relations between chemical realities and are therefore subject to the law of mass action. This implies that all drug goods, salutary or adverse, are cure related. examples of immunological responses that are fluently cure dependent include hay fever in response to high pollen counts<sup>5</sup>; the immunogenic response to hepatitis B vaccine<sup>6</sup>; desensitisation by the use of adding pilules of antigen (for illustration, cephalosporins) <sup>7</sup>; and type IV perceptivity skin responses.

b) *Time Relatedness*

multitudinous pharmacological goods depend on both the attention of the drug at the point of action and the time course of its appearance there. For illustration, a given cure of furosemide (frusemide) induces a lower diuresis when it's invested than when it's given as a gel cap. And the poison of methotrexate is lower when a low cure is given constantly than when the same total amount is given as a single cure. We distinguish two patterns of time courses of adverse drug responses, time dependent and time independent.

c) *Susceptibility*

vulnerability The trouble of an adverse drug response differs among members of an exposed population. In some cases the trouble of an adverse response will be present in susceptible subjects and absent in others. In other cases vulnerability follows a continuous distribution — for illustration, adding vulnerability with adding impairment of renal function. Although reasons for hypersusceptibility may be unknown, several types are recognized. These include heritable variation, age, commerce, physiological variation, exogenous factors, and complaint. further than one vulnerability factor can be present. (3)

### III. MATERIALS & METHODS

- 1) Settling FORWARD (Facilitation of Relating in Sanitary Ward) is an active pharmacovigilance master plan that was implemented by a group of clinic wards in the Sicilian region of Southern Italy between January 2014 and December 2015. The study was conducted in three internal medicine wards at the Giarre, Acireale, and Caltagirone hospitals as well as three geriatrics, internal medicine, and metabolic provisions wards at Messina University hospital. Each sanitarium ward has a clinical apothecary specialist examiner assigned to it. By accurately and consistently reviewing case records, the observers—who had received specialized training in pharmacovigilance—helped clinicians relate to adverse drug reactions. The Messina University Hospital Ethics Committee gave their approval to the project. Following a thorough description of the protocol design, all patients gave written informed consent, and the trial was carried out in accordance with the Declaration of Helsinki.(4)
- 2) Information Gathering: The study included all patients admitted to participating hospitals over the course of two years, and they were monitored until they were discharged. Patients who were transferred from other hospitals or wards within the study hospitals, or who were released within 24 hours, were not included. Sociodemographic traits, prior medical history, diagnoses at admission and discharge, length of stay (LOS), laboratory tests, instrumental procedures, therapies given (both prior to and during hospitalization), medications prescribed at discharge, and details on drug dosage, frequency, route, and indication of use were among the data gathered. A was used to enter the obtained data. an electronic database created on the spot. All patients were divided into three groups based on the data gathered, based on whether they had experienced at least one adverse drug reaction (ADR) (patients with ADRs that occurred during hospitalization and patients with ADRs that caused hospitalization) or not (patients without ADR). A research team of ward physicians, monitors, and clinical pharmacologists from the University Hospital of Messina's Regional Pharmacovigilance Center examined every ADR case that was discovered. (4)

- 3) Three counties in southeast Sweden Östergötland County, Jönköping County, and Kalmar County—were the sites of this investigation. Every one of the 11,015 local deaths that occurred between January 1, 2001, and December 31, 2001, was listed in the National Board's Cause of Death registry. of Welfare and Health, Sweden. A random selection was made from among the population's seven deceased. Every resident of Sweden is assigned a unique personal identification number, which enables the linking of various registers, such as case records and the Cause of Death Register. Examining a person's interactions with the healthcare system, illnesses, and medication prescriptions is therefore feasible. As a result, each research participant's complete medication history could be acquired, with special attention to the 14 days before death. The Swedish Medical Products Agency's national database for spontaneously reported ADRs was examined step-by-step, together with the death certificates, pertinent case records (from hospitals, primary care facilities, and medicolegal files), and case information. The initial assessment was carried out by four medical professionals with specialized training in ADRs. Their assessment concentrated on the clinical course of events, laboratory and/or autopsy results, and pharmaceutical treatment. Second, two pharmacists (KW, AKJ) and one clinical pharmacologist (SH) conducted a preliminary evaluation to determine whether the death was caused by a FADR. Two experts (OS, a clinical pharmacologist, and HD, a forensic pathologist) reevaluated the potential FADRs found in the initial assessment. To designate an incident as a suspected FADR, all assessors required to agree on the classification. (5)
- 4) Age, sex, length of hospital stay, and quantity of medications received were the four variations for which the findings were analyzed using a standardization technique. Comparisons of the observed distribution served as the foundation for this investigation. of patients with and without unanticipated negative effects. When all other variations are maintained constant, it is assumed that the distribution of patients with and without adverse drug responses is the same across groups based on age, sex, duration of hospital stay, or quantity of medications. In the current investigation, the predicted distributions were standardized using the process outlined by Elwood, Pemberton, Merrett, Carey, and McAulay (1965). In order to evaluate the distinct effects of a history of prior medication responses, allergic disease, or jaundice, as well as the existence of diabetes mellitus and renal disease, on the distribution of patients with adverse reactions, this standardization technique was also used for age and sex. (6)

#### IV. THE MEDICATION HISTORY

Taking a thorough medication history is important for a number of reasons:

- 1) Future treatment planning will be aided by knowing the medications a patient has taken or is now taking, as well as how they have responded to those medications.
- 2) Since medications can directly or indirectly cause illness or disease, drug effects should always be included in the differential diagnosis list.
- 3) Clinical signs can be obscured by drugs. For instance, corticosteroids can prevent rigidity and pain in the abdomen in patients with a perforated duodenal ulcer, while  $\beta$  adrenoceptor antagonists can prevent tachycardia in patients who are bleeding.
- 4) Substances can change the findings of studies. Amiodarone, for instance, modifies thyroid function testing.
- 5) To use the occasion to inform the patient about their prescription drugs.
- 6) To assist in preventing avoidable prescription errors, as a false history at hospital admission may result in unintended drug duplication, drug interactions, long-term medication discontinuation, and a failure to identify drug-related issues. (7)

##### A. Managing Adverse Drug Reactions

Handling negative drug responses Changing a dosage schedule or discontinuing a medication alleged to result in an ADR are typical techniques of handling ADRs in practice. Nonetheless, the path chosen to Handling an ADR is probably different from one clinician to another. According to EU regulations, the authorization of every new drug into the marketplace must now be paired with a solid risk management strategy from the marketing approval holder, that could entail the creation of particular therapies for overseeing particular ADRs, along with active safety studies. Such has been true for antidotes related to direct oral anticoagulants caused bleeding.(1)

##### B. Examples of Cases of ADRs

###### CASE 1:

The patient, a 64-year-old man with penicillin-allergic left lower limb cellulitis, experienced mild bronchospasm, edema, and face flushing after receiving 300 mg of intravenous vancomycin hydrochloride during a 35-minute period. Subcutaneous epinephrine, methyl prednisolone sodium succinate, and intravenous diphenhydramine hydrochloride were given when the infusion was

terminated. In four hours, the symptoms were totally gone. The skin symptoms of "red neck syndrome," which is known to happen when intravenous vancomycin is used, were present in this patient. Red neck syndrome most often happens when the medicine is given quickly, within an hour, and is closely correlated with the rate of infusion. Vasodilation brought on by histamine release seems to be the cause of the reaction. Even though a rechallenge was not conducted, it was deemed a definite adverse reaction of moderate severity due to the temporal association between the drug's administration and the reaction as well as the strong resemblance to other previously documented, well-known drug reactions.(8)

#### CASE2:

After taking 100 mg of gentamicin sulfate and 1 gram of vancomycin intravenously, a 40-year-old man with an infected arteriovenous fistula shunt developed a bright red, itchy, diffuse maculopapular rash on his trunk and limbs a few hours later. A week prior, the patient had received both medications without any problems. Before his symptoms subsided, he needed to take oral prednisone since the rash got worse and the skin became desquamated even after receiving intravenous diphenhydramine treatment. In this instance, where a reaction occurred following the administration of two distinct medications in close succession, causality was less evident. Although rash-like allergic reactions are more common when vancomycin is used than when gentamicin is used, it was impossible to definitively link the reaction to either drug; therefore, it was deemed a likely adverse reaction of moderate severity to either drug.(8)

#### CASE 3:-

Mexiletine hydrochloride was prescribed for symptomatic ventricular tachycardia in a 64-year-old man with hypertension. He experienced an episode of abnormal blood pressure increase shortly after, with readings ranging from 220/115 to 130 mm of mercury. After stopping the medication, his readings dropped back to 122/76 mm of mercury. His blood pressure increased to 220/115 mm of mercury two days after he resumed using mexiletine, but it reverted to normal after the medication was stopped. After a pheochromocytoma workup came out negative, mexiletine was looked at as a possible reason of his hypertension. There have been no reports of hypertensive aggravation or adverse effects with mexiletine or any other antiarrhythmics, according to a review of the literature and a conversation with the manufacturer. After stopping mexiletine therapy, a follow-up case showed multiple more bouts of similar blood pressure increase. This patient's labile hypertension prevented it from being classified as a definitive drug reaction, even though his hypertension was closely linked to the injection of mexiletine and an apparent rechallenge generated comparable symptoms. This hypertensive event was reported to the FDA and the drug manufacturer as a potential adverse drug reaction of moderate severity due to these uncertainties and the dearth of comparable reactions recorded in the literature. (8)

#### C. What ADRs need to be reported?

- ❖ When using "new" medications, report any suspected side effects, even mild ones. (Drugs are still regarded as "new" in many nations for up to five years following their approval for sale);
  - ❖ For medications that are well-known or established, report any serious or unexpected (strange) suspected adverse drug reactions;
  - ❖ Report any instances of a certain reaction occurring more frequently;
  - ❖ Report any suspected adverse drug reactions (ADRs) related to interactions between drugs, foods, or supplements (including complementary and herbal items);
- Report adverse drug reactions (ADRs) in specific areas of interest, such as drug abuse, drug use during pregnancy, and drug use during lactation;
- report suspected ADRs linked to drug withdrawals;
- report ADRs resulting from medication errors or overdoses;
- ❖ Report when there is a lack of efficacy or when suspected pharmaceutical flaws are found. ( 9)

Therefore, as soon as you notice an adverse reaction that you believe to be clinically significant, report it!

#### D. How to report ADRs?

The National Drug Regulatory Authority is the place to get Local Case Report Forms (CRF).

The British National Formulary, the Formularies of South Africa, Zimbabwe, and other nations have incorporated CRF into their national formularies distinct countries have distinct forms for case reports.

However, each of them has a minimum of four sections that must be finished:

- 1) Patient data:
  - Patient identification
  - Age at event or birthdate
  - Gender
  - Weight
- 2) Unfavorable incident or issue with the product
  - a description of the incident or issue
  - the date of the incident and the date of this report
  - pertinent laboratory results or tests (if available)
  - additional pertinent patient data or history
  - results attributable to an adverse event
- 3) Suspected drug or drugs:
  - name (both brand and INN)
  - dosage, frequency, and mode of use
  - therapy date
  - use diagnosis
  - incident resolved after cessation of use or a lower dose
  - batch number
  - expiration date
  - recurrence of the incident following the reintroduction of the treatment
  - dates of concurrent therapy and medical products
- 4) Journalist
  - occupation and specialty
  - name, address, and phone number (9)

## V. SEVERITY, PREVENTABILITY & CAUTION

Using previously approved and acknowledged methods, each ADR was further assessed for a number of characteristics, including cause, severity, and preventability. The Naranjo Algorithm, which has ten independently evaluated criteria, was used to evaluate causality. According to the total score, ADRs were divided into three categories: probable, possible, and finite (Naranjo et al., 1981). Hartwig's scale, which displayed the criteria and corresponding levels utilized for ADR severity assessment, served as the basis for the severity classification. An adverse drug reaction (ADR) was deemed severe if it led to either irreversible patient harm or the need for intensive medical treatment. (10)

Approach to enhance medication safety:

- 1) Steering clear of chemical functional groups that are Well known to induce toxicity during medication. design—such as, fragrant amines, aromatic compounds, epoxides and quinones.
- 2) Creation of metabolically stable medications to prevent metabolic interactions and inhibit the production of harmful metabolites—such as vigabatrin and gabapentin.
- 3) Creation of appropriate in vitro and in vivo models to clarify the function of short-lived, potentially harmful metabolites in the development of idiosyncratic toxicity.
- 4) Greater utilization of in vitro systems, like cell lines. indicating drug-metabolizing enzymes, to forecast the possibility of negative drug interactions and varied pathways of metabolism.
- 5) Examination of high-risk patients prior to market release stage of drug development to determine pharmacokinetics and pharmacological factors that affect vulnerability to medication toxicity. (11)

## VI. CONCLUSION

In this review, we explored the multifaceted aspects of Adverse Drug Reactions (ADRs), including their various types, examples, and the importance of a detailed medication history. We highlighted the methodologies used in identifying and assessing ADRs, along with established systems for reporting these reactions.

Furthermore, we discussed critical parameters such as severity, preventability, and causation—key factors that influence clinical decisions and patient outcomes. Recognizing the growing need for safer pharmacological practices, we emphasized strategic approaches to enhance medication safety, including improved reporting systems, thorough clinical assessments, and education of healthcare professionals. A comprehensive understanding and proactive management of ADRs are essential steps toward minimizing drug-related harm and ensuring patient well-being.

Here in we have discussed the identification, management and reporting of ADRs. We have described how modern technology is changing the way that ADRs are predicted, prevented, detected and managed, and how we continue to try to improve these processes with technological advances. Individualised therapy is becoming more of a possibility as not just pharmacogenetics but other phenotypic information can be combined to generate patient-specific advice to prescribers.

Such regulatory science at national and international level can help achieve a positive benefit-to-harm ratio throughout the lifecycle of a medicinal product. For individual clinicians, achieving the best outcomes from therapies remains a key goal because avoiding or mitigating the risk of ADRs continues to challenge our everyday clinical practice

Adverse drug reactions have been regarded to arise due to pharmacokinetic and pharmacodynamic variations of drug products. ADRs have been reported to exist in various types and mechanisms, depending on the health status and environmental factors of the individual. However, extensive research in the area of factors affecting the incidence and tendency of ADR's have been performed but effective integration of theory and practice is needed to safeguard the patients requiring drug therapy.

## VII. ACKNOWLEDGEMENT

The author, Vijay Nagnath Dabade, would like to express sincere gratitude to the faculty and staff of Mahadev Kanchan College of Pharmaceutical Education & Research for their constant support and encouragement throughout the preparation of this review. Special thanks are extended to all healthcare professionals, researchers, and educators whose contributions and insights have laid the foundation for a deeper understanding of adverse drug reactions (ADRs), medication safety, and pharmacovigilance. Their work continues to inspire efforts toward improving patient care and safe medication practices.

## REFERENCES

- [1] Coleman, J.J., & Pontefract SK. Adverse drug reactions. *Clin Med (Lond)*. 2016;16(5):481–485.
- [2] Rohilla, A., & Yadav, S. (n.d.). *Adverse drug reactions: An overview*. International Journal of Pharmacological Research. Retrieved from <http://www.ssjournals.com>
- [3] Aronson, J. K., & Ferner, R. E. (2003). Joining the DoTS: New approach to classifying adverse drug reactions. *BMJ*, 327(7425), 1222–1225. <https://doi.org/10.1136/bmj.327.7425.1222>
- [4] Giardina, C., Cutroneo, P. M., Mocciano, E., Russo, G. T., Mandraffino, G., Basile, G., Rapisarda, F., Ferrara, R., Spina, E., & Arcoraci, V. (2018). Adverse drug reactions in hospitalized patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) study. *Frontiers in Pharmacology*, 9, 350. <https://doi.org/10.3389/fphar.2018.00350>
- [5] Wester, K., Jönsson, A. K., Spigset, O., Druid, H., & Hägg, S. (2007). Incidence of fatal adverse drug reactions: A population-based study. *British Journal of Clinical Pharmacology*, Published online December 7, 2007. <https://doi.org/10.1111/j.1365-2125.2007.03064.x>
- [6] Hurwitz, N. (1969). Predisposing factors in adverse reactions to drugs. *British Medical Journal*, 1, 536–539.
- [7] FitzGerald, R. J. (2009). Medication errors: The importance of an accurate drug history. *British Journal of Clinical Pharmacology*, 67(6), 671–675. <https://doi.org/10.1111/j.1365-2125.2009.03424.x>
- [8] Lucas, L. M., & Colley, C. A. (1991). Recognizing and reporting adverse drug reactions. *Western Journal of Medicine*, 156(2), 172–175.
- [9] World Health Organization. (2002). *Safety of medicines: A guide to detecting and reporting adverse drug reactions—Why health professionals need to take action* (WHO/EDM/QSM/2002.2). World Health Organization. <https://apps.who.int/iris/handle/10665/67378>
- [10] Jiang, H., Lin, Y., Ren, W., Fang, Z., Liu, Y., Tan, X., Lv, X., & Zhang, N. (2022). Adverse drug reactions and correlations with drug–drug interactions: A retrospective study of reports from 2011 to 2020. *Frontiers in Pharmacology*, 13, 923939. <https://doi.org/10.3389/fphar.2022.923939>
- [11] Pirmohamed, M., Breckenridge, A. M., Kitteringham, N. R., & Park, B. K. (1998). Adverse drug reactions. *BMJ*, 316(7140), 1295–1298. <https://doi.org/10.1136/bmj.316.7140.1295>





10.22214/IJRASET



45.98



IMPACT FACTOR:  
7.129



IMPACT FACTOR:  
7.429



# INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24\*7 Support on Whatsapp)